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Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.012In this landmark year for the U.S. healthcare system, during
which the Affordable Care Act was signed into law, there
have been many notable advances in the area of heart failure
(HF) and heart transplantation. In addition to scientific
discoveries reviewed here and the publication of important
clinical guidelines, scientific statements, and state-of-the-
art reviews listed in Tables 1 and 2 (1–23), the cardiology
secondary subspecialty of advanced heart failure and trans-
plantation has been enhanced with the development of
training competencies (8) and the first American Board of
Internal Medicine Certification Examination in November
2010. In this review paper, we highlight the major published
scientific and clinical advances in clinical HF and heart
transplantation during the past academic year.
Epidemiology and Prevention
For many years, we have known that diabetes and obesity
are associated with an increased risk of incident HF.
Emerging epidemiologic studies focused on components of
that risk, including glycemic status, metabolic syndrome,
body mass index, and lipoproteins. The results of a large
Finnish study following a cohort of almost 60,000 people
demonstrated an increased risk of HF with increased body
mass index and abdominal obesity and the protective effect
of physical activity regardless of body mass index (24). In
one of several follow-up publications from the Health,
Aging and Body Composition Study, the authors observed
that fasting glucose in elderly patients without diabetes is a
predictor of incident HF (adjusted hazard ratio [HR] per 10
mg/dl: 1.10; 95% confidence interval [CI]: 1.02 to 1.18; p
0.009), independent of other HF risk factors including age,
body mass index, systolic blood pressure, history of coronary
disease, and race. Additional measures of glycemic function,
including insulin resistance, hemoglobin A1c, and oral
glucose tolerance testing, did not provide incremental pre-
dictive value (25).
Interestingly, in AMORIS (Apolipoprotein Mortality
Risk Study), which observed a large cohort of Swedish
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27, 2010, accepted January 2, 2011.patients free of cardiovascular disease, all lipoprotein com-
ponents measured were significantly associated with inci-
dent HF, with the apolipoprotein (apo)B/apoA-1 ratio
most predictive in men and triglycerides most predictive in
women. In this study, haptoglobin and uric acid were found
to add predictive value to apoB/apoA-1, but glucose did not
(26). An analysis from the Framingham Heart Study
corroborated the independent predictive value of dyslipide-
mia for incident HF (27). Although epidemiologic studies
continue to focus on these risk factors, it is still unclear what
intervention will ameliorate the risk, given the disappoint-
ing outcomes of randomized trials evaluating the effect of
statins such as CORONA (Controlled Rosuvastatin Mul-
tinational Study in Heart Failure) (28) and GISSI-HF
(Effects of n-3 PUFA and Rosuvastatin on Mortality-
Morbidity of Patients with Symptomatic CHF) (29) and
the marginally beneficial outcome with n-3 polyunsaturated
fatty acid therapy (30).
In a separate analysis of 534 patients from the Framing-
ham Heart Study, Lee et al. (31) evaluated the differences in
risk factors between patients in whom heart failure devel-
oped with reduced ejection fraction (HFREF) versus heart
failure with normal ejection fraction (HFNEF). They found
in multivariate analysis that left bundle branch block and
history of myocardial infarction reduced the odds of
HFNEF (odds ratios [ORs]: 0.21 and 0.32, respectively),
whereas atrial fibrillation, female sex, and elevated systolic
blood pressure (ORs: 4.2, 2.3, and 1.1 per 10 mm Hg,
respectively) increased the odds of HFNEF. Despite these
differences between HFNEF and HFREF, mortality was
equally dismal, with median survival of 2.1 years (31). It will
be important in the coming years to move away from
studying HF in the context of risk factors for coronary
artery disease and begin to focus on risk factors specifi-
cally associated with HF.
Risk Profiling
Global 2-dimensional strain (32) and myocardial iodine-
123 meta-iodobenzylguanidine imaging (33) were demon-
strated to prognosticate the risk of adverse events in HF
patients, although the likelihood that these expensive diag-
nostic tools will be widely available is low, especially as
regulatory constraints on cardiovascular imaging increase.
However, for centers without access to advanced cardiovas-
 Ame
1574 Owens and Jessup JACC Vol. 57, No. 15, 2011
Year in Heart Failure April 12, 2011:1573–83cular imaging or even cardiopulmonary exercise testing, a
study by Hsich et al. (34) showed that treadmill time using
the modified Naughton protocol prognosticated mortality
risk in patients with HF reasonably well. For a 1-min
change in exercise time, there was a 7% increased hazard of
death. Use of this simple and relatively inexpensive tool in
the community may facilitate evaluation by a specialized HF
and transplantation center for consideration of advanced
therapies in appropriate patients.
Biomarkers
As new biomarkers are rapidly being discovered, there are
efforts to move from a single marker risk prediction strategy
to a multimarker approach. It is evident that to be useful,
new biomarkers need to show not only independent risk
prediction but incremental value to the standard natriuretic
peptides in robust statistical analyses. Table 3 (35–43)
Guidelines and Scientific StatementsTable 1 Guidelines and Scientific Statements
Clinician’s Guide to Cardiopulmonary Exercise Testing in Adults: A Scientific Stateme
The International Society of Heart and Lung Transplantation Guidelines for the Care
Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Task Fo
European Society of Cardiology and the European Respiratory Society, Endorsed b
HFSA 2010 Comprehensive Heart Failure Practice Guideline (4)
Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed
International Society for Heart and Lung Transplantation Working Formulation of a S
State of the Science: Promoting Self-Care in Persons With Heart Failure: A Scientific
ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Managemen
A Report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training
ACCF/AHA 2010 Position Statement on Composite Measures for Healthcare Perform
American Heart Association Task Force on Performance Measures (Writing Comm
Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of P
Heart Failure Association of the European Society of Cardiology Working Group on
2010 Focused Update of ESC Guidelines on Device Therapy in Heart Failure: An Upd
Chronic Heart Failure and the 2007 ESC Guidelines for Cardiac and Resynchroniza
and the European Heart Rhythm Association (11)
ACCF  American College of Cardiology Foundation; ACP  American College of Physicians; AHA
State-of-the-Art ReviewsTable 2 State-of-the-Art Reviews
Basic Science of Pulmonary Arterial Hypertension for Clinicians:
New Concepts and Experimental Therapies (12)
Atrial Fibrillation and Heart Failure: Treatment Considerations for
a Dual Epidemic (13)
Enhancing the Outcome of Cell Therapy for Cardiac Repair:
Progress From Bench to Bedside and Back (14)
Cardiorenal Syndrome: New Perspectives (15)
Mitral Valve Surgery in Advanced Heart Failure (16)
Palliative Care in Congestive Heart Failure (17)
Assessment of Nonischemic Myocardial Fibrosis (18)
Use of Genetics in the Clinical Evaluation of Cardiomyopathy (19)
The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure (20)
Selection of Cardiac Transplantation Candidates in 2010 (21)
Appropriate Evaluation and Treatment of Heart Failure Patients After
Implantable Cardioverter-Defibrillator Discharge: Time to Go Beyond
the Initial Shock (22)
Clinical Management of Continuous-Flow Left Ventricular Assist Devices in
Advanced Heart Failure (23)outlines several markers that have emerged and may be
included in future multimarker strategies. A recent analysis
of more traditional biomarkers—troponin T, B-type natri-
uretic peptide (BNP), and C-reactive protein—showed that
use of 2 biomarkers in combination was superior to a single
biomarker for risk prediction (44). There is considerable
research on how to optimally use multiple biomarkers in a
practical manner. In addition, there is no consensus on how
to use biomarkers to specifically direct therapy. Ultimately,
if integration of a panel of biomarkers as part of an objective
prognostic scoring system along with standard clinical
variables is accomplished, there may be less reliance on
relatively subjective endpoints such as symptoms and New
York Heart Association (NYHA) functional class. Unfor-
tunately, evidence supporting serial marker management
strategies using natriuretic peptides is still lacking, as evi-
denced by the neutral results of the BATTLESCARRED
(NT-proBNP Assisted Treatment to Lessen Serial Cardiac
Readmissions and Death) trial and RED HOT II (Rapid
Emergency Department Heart Failure Outpatients Trial)
(45,46).
Pathophysiology
As outlined last year by Tang and Francis (47), the complex
and important role of microribonucleic acid (miRNA)-
mediated control of gene expression during cardiac muscle
disease development continues to be the subject of reviews
(48,49) and investigation. One example of the latter is from
van Rooij et al. (50) who showed that 3 myosin genes,
Myh6, Myh7, and Myh7b, encode related intronic miRNAs,
which, in turn, control muscle myosin content, myofiber
identity, and muscle performance. As reviewed by Williams
et al. (49), the integration of miRNAs into the core muscle
transcriptional program expands the precision and complex-
ity of gene regulation in muscle cells because individual
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Another example acknowledges that proper function of the
heart depends on the expression of myosin heavy chain
(MHC) proteins MYH6 (-MHC) and MYH7 (-
HC). Cardiac injury results in a decrease in the expression
f the adult myosin gene Myh6 and an increase in the
expression of the embryonic myosin geneMyh7. Williams et
al. (49) summarized that global profiling of miRNAs in
different forms of human heart disease demonstrated that
miRNA gene expression signatures are diagnostic for dis-
tinct but related forms of heart disease such as dilated
cardiomyopathy, ischemic cardiomyopathy, and aortic ste-
nosis. In this regard, miRNA-based diagnostics are likely to
emerge as a useful means of molecularly defining specific
forms of heart disease and disease progression.
Genetics and genomics of HF. In a prospective cohort
study of 2,000 patients with HF, including both Cauca-
sians and African Americans, Cresci et al. (51) found that
genetic polymorphisms of the 1-adrenergic receptor and a
kinase that terminates its signaling, GRK5, can significantly
affect HF outcomes. They further reported that adjusting
for these gene variants abrogates the apparent ethnic differ-
ences in beta-blocker treatment effect on HF survival. These
findings support additional investigations into the determi-
nants of response to a variety of HF therapies, moving away
from only phenotypical characterizations. In a retrospective
Established and Emerging Biomarkers in HFTable 3 Established and E erging Biomarkers in HF
Biomarker (Ref. No.) Postulated Pathophysiology
Soluble ST2 (35) A member of the interleukin-1 receptor fam
identified as a potential mediator of
myocardial fibrosis. The ligand for ST2 is
interleukin-33.
Galectin-3 (36) Affects the synthesis of new matrix compon
such as type I collagen and influences th
degradation of extracellular matrix
components through a set of tissue inhib
metalloproteinases and matrix
metalloproteinases
Neuregulin-1 (38) Released from microvascular endothelial ce
and acts as a paracrine factor via the Erb
family of tyrosine kinase receptors expre
in cardiac myocytes to regulate myocyte
differentiation and stress response
Copeptin
(C-terminal pro-vasopressin) (39)
Essential in fluid retention and hyponatremi
patients with HF, causing vasoconstrictio
and left ventricular remodeling
Mid-region pro-adrenomedullin (40) Vasodilatory peptide with potent
hypotensive effects
Mid-region pro-atrial natriuretic
peptide (40)
Vasodilatory peptide with potent
hypotensive effects
Red cell distribution width (41,42) Measure of the variation in cell volume with
the circulating erythrocyte population
Soluble TNF-like weak inducer of
apoptosis (sTWEAK) (43)
A multifunctional cytokine and member of t
TNF family, which regulates cell growth,
migration, and survival
BNP  B-type natriuretic peptide; CI  confidence interval; HF  heart failure; HR  hazard r
YHA  New York Heart Association; OR  odds ratio; TNF  tumor necrosis factor.analysis of subjects enrolled in the Genetic Risk Assessmentin HF substudy of A-HeFT (African American Heart
Failure Trial), the authors reported a pharmacogenetic
interaction in African Americans with systolic HF carrying
the dysfunctional corin allele I555(P568). This allele is
almost exclusively present in people of African descent and
is postulated to contribute to impaired processing of BNP.
In this study, which has not yet been replicated, subjects
who were heterozygous for the allele had an increased risk of
death or HF hospitalization compared with noncarriers.
Additionally, in the randomized subjects of the A-HeFT
substudy who were already treated with neurohormonal
blockade, this risk was mitigated by treatment with fixed-
dose isosorbide dinitrate and hydralazine (52). In a related
publication, Matkovich et al. (53) demonstrated the accu-
racy and utility of pooled sequencing to identify previously
unknown rare gene variants to compare polymorphism
expression among different populations and to identify
novel associations between a cardiac signaling subgenome,
HSPB7 polymorphisms, and sporadic systolic HF. The
power and potential applicability of this strategy may pave
the way for additional insights into the variability of the
syndrome of HF.
Evidence strongly supporting a genetic basis for many
cardiomyopathies currently classified as idiopathic or sec-
ondary to myocarditis continues to grow as we discover new
genetic mutations associated with dilated cardiomyopathy.
Study Population Correlation With Outcome
LVEF 45%,
NYHA functional class II–III
OR: 1.39 (95% CI: 1.09–1.78, p  0.006)
for sudden cardiac death
Mean LVEF 31%,
NYHA functional class III–IV
HR: 1.24 (95% CI: 1.03–1.50, p  0.026)
for mortality in a full model with
patient variables and NT-proBNP (37)
Mean LVEF 32%,
NYHA functional class I–IV
HR: 1.58 (95% CI: 1.04–2.39, p  0.03)
for death or transplantation
Mean LVEF 33%,
NYHA functional class II–IV
Not predictive for mortality in a robust
model
Patients presenting with dyspnea
to the emergency department
Superior to BNP and NT-proBNP for
predicting 90-day mortality
Patients presenting with dyspnea
to the emergency department
Equivalent to BNP or NT-proBNP in the
diagnosis of HF in patients presenting
with dyspnea
LVEF 40%,
NYHA functional class I–IV;
NYHA functional class III–IV
HR: 1.12 (95% CI: 1.05–1.16, p  0.001)
for death; HR: 1.06 (95% CI: 1.01–1.11,
p  0.022) for death
LVEF 40%,
NYHA functional class I–III
HR: 1.9 (95% CI: 1.3–2.6, p  0.0012)
for death
EF  left ventricular ejection fraction; NT-proBNP  N-terminal pro–B-type natriuretic peptide;ily,
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counseling (19,54). An extensive linkage study in 2 unre-
lated multigenerational families was reported by Lakdawala
et al. (55) that established the pathogenicity of a novel
missense mutation in the alpha-tropomyosin gene. Notably,
in vitro functional analyses revealed opposite effects in
calcium handling in the D230N alpha-tropomyosin muta-
tion, which leads to dilated cardiomyopathy, and the
D175N alpha-tropomyosin mutation, which leads to hyper-
trophic cardiomyopathy.
Three additional genetic studies published this year
identified novel dilated cardiomyopathy genes. Brauch et al.
(56) identified missense mutations in exon 9 of RNA
binding motif protein 20 (RMB20), Moulik et al. (57)
identified mutations in ANKRD1, the gene encoding car-
diac ankyrin repeat protein, and Hassel et al. (58) identified
mutations in NEXN, the gene encoding nexilin, a novel
Z-disk protein. Interestingly, a fourth genetic study found
an association between HF and a single nucleotide poly-
morphism in the gene KCNE1, which modulates potassium
current and has previously been associated with atrial
fibrillation. In this preliminary study, confirmed in a second
population, both of which excluded patients with atrial
fibrillation, the S38G polymorphism at the KCNE1 locus
odulated predisposition to HF (59).
anagement of HF
harmacologic therapy. This year witnessed ongoing ex-
loration of the role of aldosterone antagonists in the
anagement of HF. In a clinically stable population of
atients with mild to moderate HF symptoms and HFREF,
6 weeks of treatment with eplerenone added to optimal
edical therapy had no detectable effect on parameters of
V remodeling (60). However, Bansal et al. (61) outlined a
ersuasive argument for the use of high-dose aldosterone
ntagonists in patients with resistance to commonly used
oop diuretics. In patients with decompensated or advanced
F with volume overload, natriuretic doses of aldosterone
ntagonists (spironolactone50 mg/day) may be an option.
he competitive natriuretic response of aldosterone antag-
nists is related to activity of the renin-angiotensin-aldosterone
ystem. The higher the renin-angiotensin-aldosterone system
ctivity is, the higher the dose of aldosterone antagonist
equired to produce natriuresis. In addition, a post hoc
nalysis of EPHESUS (Eplerenone Post-Acute Myocardial
nfarction Heart Failure Efficacy and Survival Study) sug-
ests that earlier eplerenone initiation, 7 days post-
yocardial infarction complicated by systolic dysfunction
nd HF, was safe and associated with better outcomes that
ere not observed when the drug was administered after 1
eek (62). Another study noted that less than one-third of
ligible patients hospitalized for HF and participating in a
uality improvement registry received HF guideline–
ecommended aldosterone antagonist therapy (63). We
wait the results of the EMPHASIS-HF (Effect of Epler- Inone Versus Placebo on Cardiovascular Mortality and
eart Failure Hospitalization in Subjects with NYHA
lass II Chronic Systolic Heart Failure) to delineate the
pectrum of HF patients who may benefit from aldosterone
ntagonism.
Several other HF management strategies were high-
ighted this year. The HEAAL (Effects of High-dose
ersus Low-dose Losartan on Clinical Outcomes in Pa-
ients with Heart Failure) study demonstrated that losartan
50 mg daily reduced the rate of death or hospital admission
or HF in patients with HF, left ventricular ejection fraction
40%, and intolerance of angiotensin-converting enzyme
ACE) inhibitors compared with losartan 50 mg daily.
hese findings show the value of up-titrating angiotensin
eceptor blocker doses to confer clinical benefit (64). The
AIR-HF (Ferinject Assessment in Patients with Iron
eficiency and Chronic Heart Failure) trial showed that
reatment with intravenous ferric carboxymaltose in patients
ith chronic HF and iron deficiency, with or without
nemia, improved symptoms, functional capacity, and qual-
ty of life with a reasonable side-effect profile (65). We also
earned more about beta-blocker use in different popula-
ions. During acute HF, a study revealed that continuation
f beta-blocker therapy was not associated with delayed or
ess improvement, but rather with a higher rate of long-term
rescription of beta-blocker therapy after 3 months (66). In
second study, initiation of bisoprolol in patients with HF
nd concomitant moderate or severe obstructive pulmonary
isease resulted in a reduction in forced expiratory volume in
s. However, symptoms and quality of life were not
mpaired (67). The summer ended with the intriguing
HIFT (Systolic Heart Failure Treatment with If Inhibitor
vabradine Trial), showing improved outcomes with ivabra-
ine added to standard HF therapy (68). The role of this
rug that primarily slows heart rate will be debated for some
ime with respect to patients already on optimal doses of
eta-blockers.
onpharmacologic therapy. Investigators continue to
earch for optimal methods and reasons to treat sleep apnea
nd HF. Gottlieb et al. (69) prospectively followed a total of
,927 men and 2,495 women 40 years of age and older and
ree of coronary heart disease and HF at the time of baseline
olysomnography. After adjustment for multiple risk fac-
ors, obstructive sleep apnea was a significant predictor of
ncident coronary heart disease only in men 70 years of age
nd younger but not in older men or in women of any age.
asai et al. (70) suggest that patients with coexisting
bstructive sleep apnea and Cheyne-Stokes respiration–
entral sleep apnea may receive greater benefit from treat-
ent with flow-triggered adaptive servoventilation than
ith continuous positive airway pressure alone. Gottlieb et
l. (71) found that in patients with stable HF, changes in
NP during the night were related to the severity of
octurnal hypoxemia rather than the frequency or type of
leep-disordered breathing episodes or associated arousals.
nterestingly, Yumino et al. (72) argue the novel concept
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genesis of both obstructive and central sleep apnea in
patients with HF. The magnitude of overnight rostral fluid
movement contributed not only to the severity of sleep
apnea but also to its predominant type. This fluid shift was
directly related to the degree of leg edema and sitting time
and inversely related to the degree of physical activity, giving
us possible clues to therapeutic interventions. It is our hope
that advances in the pathophysiology and treatment of sleep
disorders will lead to therapies that promote patient com-
pliance as the compliance rate with continuous positive
airway pressure remains suboptimal.
Remote Patient Monitoring
To combat the growing societal cost of repeated hospital-
izations among chronic HF patients, American and Euro-
pean guideline committees have encouraged the use of
remote patient monitoring, using a combination of struc-
tured telephone communication and electronic transmission
of physiologic parameters through the use of external or
implantable monitoring devices. The largest meta-analysis
to date confirmed that this approach decreases mortality and
hospitalizations (73). Importantly, a follow-up study from
the DIAL (Randomized Trial of Telephonic Intervention
in Chronic Heart Failure) concluded that a reduction in HF
hospital admissions was sustained at 3 years, even after the
telephone intervention ended (74). With regard to implant-
able devices, 2 studies evaluated patients with thoracic
impedance monitoring and found that significant decreases
in thoracic impedance are associated with a statistically
significant risk of subsequent HF hospitalization (75,76).
With an abundance of data continuously available, it
becomes critical to know how to monitor and react to daily
changes in impedance and, furthermore, which member of
the multidisciplinary team should be held responsible for
interpretation of data. Whellan et al. (77) report that a
monthly review of diagnostic data obtained from patients
with pacing or defibrillator devices identified patients with
significantly increased risk (HR: 4.8, 95% CI: 2.9 to 8.1;
p  0.001) for subsequent hospitalization with acute HF
after adjusting for clinical variables. Finally, in a pilot
study of an investigational left atrial pressure monitor in
the HOMEOSTASIS (Hemodynamically Guided Home
Self-Therapy in Severe Heart Failure Patients) trial, the
concept of physician-directed patient self-monitoring led to
statistically significant improvements in NYHA functional
class, left ventricular ejection fraction, up-titration of ACE
inhibitors and beta-blockers, and a decrease in loop diuretic
dose with twice-daily readings that dictated daily medica-
tion dose and dietary allowances (78).
Transplantation
As outcomes after cardiac transplantation continue to im-
prove, an ongoing goal has been to develop a noninvasive,
cost-effective, and accurate method of surveillance for rejec-tion to replace the current gold standard of endomyocardial
biopsy. Two promising studies report results of using gene
expression profiling of peripheral blood samples to diagnose
and survey for acute rejection in transplant patients at low
risk of rejection (79,80). In perhaps a complementary
approach, cardiac magnetic resonance imaging showed po-
tential for utility in noninvasive diagnosis (or confirmation)
of acute allograft rejection (81). As noted previously, guide-
lines for the management of patients after transplantation
were published this year (2).
Mechanical Assist Devices
Debate continues regarding appropriate patient selection for
mechanical circulatory support and optimal timing of left
ventricular assist device implantation. High on the priority
list are risk scoring systems that can accurately predict which
patients are likely to do well after implantation. In a
recent paper comparing several risk scores with multivar-
iate analysis, the Seattle HF Model (HR: 1.50, 95% CI:
1.02 to 2.21; p  0.04) and APACHE II (HR: 1.10, 95%
CI: 1.01 to 1.21; p  0.04) best predicted 1-year
mortality. The overall best predictor of mortality in a
single institutional cohort of continuous-flow left ven-
tricular assist device patients was the Seattle score (82).
Meanwhile, the INTERMACS Coordinators’ Council
identified gaps in the clinical characterization of hospital-
ized patients on temporary mechanical circulatory support
devices and of homebound patients with resting symptoms,
which led to revised definitions of 2 profiles and the
addition of new modifiers: 1 for temporary mechanical
circulatory support devices in the hospital and 1 for frequent
rehospitalization of patients at home (83). It is also grati-
fying to note that patient thresholds for left ventricular assist
device insertion parallel objective survival and functional
data, reported by Stewart et al. (84). From their interview of
105 patients with symptomatic HFREF, most would be
receptive to referral for discussion of left ventricular assist
device by the time expected mortality is within 6 to 12
months and activity is limited to 1 block.
A follow-up publication from the HeartMate II (Thor-
atec Corp., Pleasanton, California) left ventricular assist
device as a bridge to transplantation study reported normal-
ized hepatic and renal function within 1 month of
continuous-flow left ventricular assist device implantation
with normal function continuing up to 6 months (85). A
randomized, controlled trial of a pulsatile-flow device
(HeartMate XVE) versus a continuous-flow device (Heart-
Mate II), in a population ineligible for transplantation,
showed that the continuous-flow device is superior, with
increased rate of survival, quality of life, exercise capacity,
and device durability (86). With these promising results, the
HeartMate II left ventricular assist device was approved by
the U.S. Food and Drug Administration for destination
therapy. However, as we accumulate longer follow-up time
with destination therapy, there is growing evidence of
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brovascular) with continuous flow, perhaps on the basis of
arteriovenous malformations in conjunction with acquired
von Willebrand syndrome (87). The complete pathophysi-
ology of this clinically relevant adverse effect is not yet
understood.
Novel Therapeutics
Several new therapeutic approaches targeted myocardial
calcium handling this year, including gene therapy with
AAV1/SERCA 2a in the CUPID (Efficacy and Safety
Study of Genetically Targeted Enzyme Replacement Ther-
apy for Advanced Heart Failure) trial (88), infusion of
recombinant human neuregulin-1 (89), and the administra-
tion of apelin (90). These studies highlight the growing
concept that inotropy can have salutary effects depending on
the mechanism of increased contractility, in distinction to
the deleterious long-term effects of inotropy via phospho-
diesterase inhibitors.
The largest study to date investigating the role of intra-
coronary autologous transplantation of bone marrow-
derived stem cells in chronic ischemic cardiomyopathy was
published this year. The STAR (Acute and Long-term
Effect of Intracoronary Stem Cell Transplantation in
Chronic Heart Failure) heart study was a prospective,
nonrandomized, open-label study comparing hemodynam-
ics, left ventricular function, exercise capacity, arrhythmias,
and mortality in 191 patients who received bone marrow–
derived stem cells and 200 control patients who refused
infusion of bone marrow–derived stem cells but consented
to all other testing. There were statistically significant
improvements in all parameters, including mortality, at
approximately 5 years of follow-up, with an average mor-
tality rate in the treated group of 0.75% per year versus
3.68% in the control group (91).
Because of the concordant results of countless trials
showing the efficacy of ACE inhibition in HF, it is
well-known that angiotensin I– converting enzyme, a
membrane-bound zinc metallopeptidase, converts the pro-
hormone angiotensin I to angiotensin II and inactivates
bradykinin. The identification of an ACE-independent
mast cell pathway for angiotensin II generation in the
human heart raised the possibility that long-term ACE
inhibitor therapy may not completely suppress angiotensin
II, which may in turn cause adverse left ventricular remod-
eling by activating angiotensin II receptor subtypes 1 and 2.
Chymase, an angiotensin II–forming serine protease found
mainly in mast cells and the human heart, is also found in
the cardiac interstitial space. Using mice and hamster
models, Wei et al. (92) showed that chymase inhibition
decreased left ventricular interstitial fluid space angiotensin
II levels substantially, indicating the importance of mast cell
chymase in regulating cardiac angiotensin II levels. These
results suggest that chymase inhibitors could be a useful
addition to ACE inhibitor therapy in the treatment of HF. aCardiorenal Syndrome
Elucidating cardiorenal interactions more completely re-
mains a major challenge in the field, both mechanistically
and clinically. A timely review by Bock and Gottlieb (15)
summarizes the scope of the problem and the complex
mechanisms involved in the pathophysiology. Clinically,
observations from 2 retrospective subgroup analyses were
particularly thought provoking. The first, using data from
COACH (Coordinating Study Evaluating Outcomes of
Advising and Counseling in Heart Failure), concluded that
worsening renal function at any time from admission for
acute HF until 12 months of follow-up was associated with
an increased risk of rehospitalization for HF or mortality:
HR: 1.63 (95% CI: 1.10 to 2.40; p  0.014) for in-hospital
worsening renal function, HR: 2.06 (95% CI: 1.13 to 3.74;
p  0.018) for worsening renal function between 0 and 6
onths, and HR: 5.03 (95% CI: 2.13 to 11.88; p  0.001)
or worsening renal function between 6 and 12 months after
ischarge (93). This study suggests that accurate risk pro-
ling of this vulnerable population should take into account
hanges in renal function for much longer than the standard
dmission period and calls into question the mechanism by
hich worsening renal function is occurring in this subset of
atients. A retrospective analysis of the ESCAPE (Evalua-
ion Study of Congestive Heart Failure and Pulmonary
rtery Catheterization Effectiveness) dataset reported that
ubjects experiencing hemoconcentration during treatment
or acute HF received significantly higher doses of loop
iuretics, had higher odds of developing worsening renal
unction (OR: 5.3; p  0.001), and had decreased adjusted
ortality at 180 days (HR: 0.16; p  0.001) (94). Clearly,
e do not yet have a grasp of the intricate interplay between
he heart and the kidney that leads to changes in renal
unction or how to predict which patients are at increased
isk of mortality when their renal function changes. A final
onfounder in many of these studies is the inconsistent
efinition of worsening renal function. Large prospective
linical trials in this area are anticipated and sorely needed.
rrhythmias and Device Therapy for HF
he excitement created by REVERSE (Resynchroniza-
ion Reverses Remodeling in Systolic Left Ventricular
ysfunction) (95) and MADIT-CRT (Multicenter Au-
omatic Defibrillator Implantation Trial with Cardiac
esynchronization Therapy) (96) is ongoing; echocardio-
raphic observations from both studies have revealed that
ardiac resynchronization therapy (CRT) in patients with
YHA functional class I and II resulted in major
tructural and functional reverse remodeling, which ap-
eared to correlate with outcome (97,98). We expect that
he RAFT (Resynchronization–Defibrillation for Ambula-
ory Heart Failure Trial) will further elucidate the possible
urvival benefit afforded by CRT in addition to the implant-
ble cardioverter-defibrillator (ICD) in NYHA functional
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CRT resulted in an improvement in short-term hemody-
namic variables in patients with a QRS 120 ms related to
both contractile improvement and relief of external con-
straint. Another team showed that in patients with HFREF
and atrioventricular block requiring permanent ventricular
pacing, CRT is superior to right ventricular pacing alone
and should be considered the preferred pacing mode (100).
In the midst of this enthusiasm came the sobering observa-
tion that endpoints in multiple CRT trials correlated poorly,
which severely limits our ability to generalize results over
multiple studies (101). Future trial designs will need to
address this critical deficiency.
The role and implications of ICD therapy were further
refined this year. Mishkin et al. (22) demonstrated that
aggressive HF surveillance and management are required
after an ICD shock because the risk of sudden cardiac death
is transformed to an increased HF event risk. A clinical risk
prediction model identified subsets of moderately symptom-
atic HF patients in the SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial) in whom single-lead ICD
therapy was of no benefit and other subsets in which benefit
was substantial (102). As extracellular matrix alterations
affect the arrhythmogenic substrate in nonischemic dilated
cardiomyopathy, Kanoupakis et al. (103) observed that
serum markers of collagen turnover could predict arrhyth-
mic events in ICD recipients. Finally, in a study of the
clinical effectiveness of ICDs among older Medicare bene-
ficiaries hospitalized with HF, ICDs were associated with a
significantly lower relative risk of mortality over 3 years
compared with no ICD use, after adjustment for the
probability of treatment, other prognostic variables, and
medical therapy at discharge (104).
HFNEF
The search to understand the pathophysiology leading to
HFNEF continues. A small case-control study by Phan et
al. (105) investigated the mechanism of HFNEF using
echocardiographic techniques during rest and exercise. Sig-
nificant differences between cases and controls in radial and
longitudinal strain, delayed diastolic ventricular untwisting,
reduced mitral annular velocities, and abnormal systolic
rotation were observed. They hypothesized that symptoms
during exercise in patients with HFNEF are more attribut-
able to these abnormalities in function than to abnormal
myocardial stiffness, which has been observed in other
studies. In one such study, an observational investigation
from the Rochester Epidemiology Project, Borlaug et al.
(106) found that ventricular-arterial coupling is maintained
in hypertensive patients with normal ejection fraction with
and without HF. Further, they report that end-systolic
stiffness and myocardial contractility are increased in hyper-
tensive patients without HF. In contrast, in hypertensive
patients with HFNEF, end-systolic stiffness is increased,
but myocardial contractility is decreased. They postulate Athat passive stiffening may contribute to the phenotype of
HFNEF in the setting of decreased contractility. A
follow-up cross-sectional study by the same group con-
firmed impairment of chronotropic, contractile, endothelial,
and vascular reserve in subjects with HFNEF compared
with hypertensive and normal controls (107).
In a small, open-label, randomized study evaluating the
effect of eplerenone on measures of collagen turnover in
HFNEF, the authors concluded that eplerenone at a 50-mg
dose modestly attenuated the increase of pro-collagen type
III aminoterminal peptide but unfortunately had no effect
on clinical symptoms, BNP, or inflammatory markers (108).
nother study investigated the mode of death in HFNEF.
n contrast to a recent community-based study from the
ayo Clinic showing that 49% of patients died of noncar-
iovascular causes (109), analysis of the randomized
-PRESERVE (Irbesartan in Heart Failure with Preserved
jection Fraction) data confirmed that the majority (60%)
f subjects with HFNEF do succumb to cardiovascular
eath, with sudden death (26%) and HF (14%) proving
ost common and an annual mortality rate of 5.2% among
rial participants, unaffected by treatment with irbesartan
110). Zile et al. (110) postulate that perhaps the older
verage age of patients with HFNEF and accompanying
ncreased number of comorbidities compared with patients
ith HFREF account for the relative difference between
ardiac and noncardiac cause of mortality between these 2
roups.
omorbidities
ulmonary hypertension. Pulmonary hypertension sec-
ndary to left heart disease continues to be an area in need
f randomized clinical trials assessing the efficacy of avail-
ble therapeutics including endothelin receptor antagonists,
hosphodiesterase-5 inhibitors, and prostanoids. Guidelines
rom the European Society of Cardiology (3) and from the
th World Symposium on Pulmonary Hypertension (111)
ere published, but unfortunately the strength of evidence is
acking for many recommendations, especially with respect
o the so-called nonpulmonary arterial hypertension pulmo-
ary hypertension.
There were 2 clinical trials of treprostinil reported for
he treatment of pulmonary arterial hypertension. The
RIUMPH I (Clinical Investigation into the Efficacy and
olerability of Inhaled Treprostinil Sodium in Patients with
evere Pulmonary Arterial Hypertension) showed improved
xercise capacity and quality of life with inhaled treprostinil
n combination with sildenafil or bosentan (112), and a
maller placebo-controlled trial of 44 patients treated with
ntravenous treprostinil revealed safety and improvement in
ymptoms, exercise capacity, and functional class (113). A
horough review of the basic science of pulmonary arterial
ypertension and novel therapeutic targets was published by
rcher et al. (12).
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pathogenesis and treatment of peripartum cardiomyopathy
and pregnancy-associated cardiomyopathy were reported
independently by several groups. Genetic testing of peripar-
tum cardiomyopathy patients suggested that a subset have a
genetic basis for their disease, including mutations that are
known to segregate in familial dilated cardiomyopathy.
Furthermore, a number of first-degree relatives of peripar-
tum cardiomyopathy patients were found to have undiag-
nosed dilated cardiomyopathy when screened (114,115).
These important findings may lead to changes in the
guidelines to reflect the utility of screening first-degree
relatives of patients with these pregnancy-related disorders.
Meanwhile, in an open-label, randomized, pilot study of
subjects with acute peripartum cardiomyopathy, bromocrip-
tine in addition to standard HF therapy was found to
significantly improve outcome at 6 months (defined as
superior survival, ejection fraction, and NYHA functional
class) compared with standard therapy alone, without ad-
verse side effects (116). We expect larger clinical trials of this
promising new therapy as well as mechanistic studies to
emerge in the coming months.
Conclusions
This academic year has witnessed an absence of blockbuster
therapies for HF, but important insights and discoveries
have been made nonetheless. There is an emerging sense of
the importance of the implementation of guidelines to
individual vulnerable patients and increasing exploration of
methods that may allow us to optimize care for all patients
(117,118). Our basic science colleagues are uncovering novel
targets for therapies that seem right around the corner.
There is hope for the HF patient.
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